A trial of Furosemide (FUROSCIX®) for the of treatment of edema in patients with chronic kidney disease (CKD) including nephrotic syndrome

At a glance
Trial Overview
Trial Details
Interventions
Trial History
References

Trial Profile

A trial of Furosemide (FUROSCIX®) for the of treatment of edema in patients with chronic kidney disease (CKD) including nephrotic syndrome

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Furosemide (Primary)
Indications Oedema
Focus Adverse reactions

Most Recent Events

07 Mar 2025 New trial record
06 Mar 2025 According to a scPharmaceuticals media release, company announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication to include treatment of edema in patients with chronic kidney disease (CKD).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com